Skip to main content

Biliary Cancer clinical trials at UCSF
1 in progress, 1 open to new patients

  • Pembrolizumab and GM-CSF in Biliary Cancer

    open to eligible people ages 18 years and up

    This is an open label phase II trial to examine efficacy and safety of a novel combination of pembrolizumab plus induction GM-CSF in patients with advanced biliary cancers treated at UCSF. This phase II study will examine the efficacy and safety of the novel combination of pembrolizumab plus induction GM-CSF in advanced biliary cancer patients with the hypotheses that the combination may increase proportion of patients with PFS6 compared to contemporary historical controls, with acceptable safety.

    San Francisco, California